22.
Issues regarding labelling and the unblinding of investigational medicinal products shall be addressed in the protocol, where necessary.
← anx_I__cpt_4__point_21__text_1 · All articles · anx_I__cpt_4__point_22__text_1 →
Source: EUR-Lex (Cellar) · retrieved 2026-11-06 · Text as adopted (Official Journal); later amendments are not incorporated in this text.